Navigation Links
Three Johns Hopkins researchers named Howard Hughes Medical Institute early career scientists
Date:3/26/2009

Three researchers at the Johns Hopkins University School of Medicine have been named early career scientists by the Howard Hughes Medical Institute (HHMI). Xinzhong Dong, Ph.D., Joshua Mendell, M.D., Ph.D., and Sinisa Urban, Ph.D., all will remain faculty at Hopkins but also become employees of HHMI, which will provide research funding and salary for the next six years.

"We are thrilled for Xinzhong, Josh and Sin for being recognized by Hughes for the quality of their work," says Chi V. Dang, M.D., Ph.D., the vice dean for research at Johns Hopkins. "At the same time, this is an honor for all of Johns Hopkins, to have not only one but three young investigators selected."

The award is given to recognize "the nation's best biomedical scientists at a critical early stage of their faculty careers, and to provide them with flexible funding to develop scientific programs of exceptional merit."

Dong, an assistant professor of neuroscience and member of Hopkins' Institute of Basic Biomedical Sciences Center for Sensory Biology, has been at Johns Hopkins since 2004. His team is taking a multidisciplinary approach to understanding the mechanisms behind sensation, including pain, itch and touch. All three so-called somatosensations are controlled by nerves in the dorsal root ganglia, a bundle of nerves that carries information through the spinal cord into the brain. To do their research, the team has developed new molecular tools to examine nerve cell circuitry and communication. They would like to learn which nerve cells mediate which sensation, how these nerve cells relay information to other cells and which proteins within these cells actually sense an itch or gentle touch.

Mendell has been an assistant professor of pediatrics and member of Hopkins' McKusick-Nathans Institute of Genetic Medicine since 2004. His team studies microRNAs, how they function and how they are controlled in normal cells and under disease conditions. MicroRNAs, small RNA molecules that affect the stability of messages and the amount of proteins made by genes, can control many aspects of development and cell function and often are altered in diseases such as cancer. Mendell's team was one of the first to identify microRNAs that are involved in cancer-promoting molecular pathways. In addition to their work on cancer, the team also studies how microRNAs are controlled within a cell and how that control is lost in disease states.

Urban has been an assistant professor of molecular biology and genetics since 2006. His team studies enzymes called rhomboid proteases that are found in a cell's membrane. Urban discovered that rhomboid proteases catalyze a biochemical reaction that cuts proteins. His research team aims to understand the biochemical principles governing how catalysis occurs embedded within the membrane, which is a new frontier in biochemistry. They also focus on how deadly pathogens such as malaria and related parasites use rhomboid proteases to infect human cells, and how parasitic amebae use rhomboids to evade the immune system. Uniting these studies may lead to new drug development because targeting rhomboid enzymes with inhibitors may be an effective way to treat multiple infectious diseases.


'/>"/>

Contact: Audrey Huang
audrey@jhmi.edu
410-614-5105
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Avidas(TM) Pharmaceuticals Introduces Scalacort(TM) DK Which Offers Three Scalp Solutions in One Patient Convenience Kit
2. Three New NextCare Immediate Care Clinic Locations Open in Colorado
3. Leader in Health Plan Cost Containment Cites Three Economy-Driven Reasons Why Self-Insured Health Plans Should Brace for Claim Increases and Fund Reserves Accordingly
4. Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing
5. Three Leading Proxy Advisory Firms are Unanimous in Recommending LCA-Vision Stockholders Support the Current Board of Directors
6. Living With Grief: Diversity and End-of-Life Care' National Teleconference Offered at Three Bay Area Locations
7. Promising Three-year Data: Saving Limbs With Drug-Eluting Stents
8. Three Cetaphil(R) Products Awarded National Eczema Association Seal of Acceptance
9. United States Joins Suit Against Community Health Systems Inc. and Three of Its Hospitals in New Mexico
10. Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members
11. Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The TouchPoint Solution’s ... the Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch about the ... , Project Entrepreneur’s second annual venture competition ignites bold ideas by providing women access ...
(Date:3/27/2017)... , ... March 27, 2017 , ... The Case Management ... of Directors on June 30, 2017. CMSA’s membership has elected their upcoming President-Elect, ... our current Military Advisory position, a new VA Advisory position has also been added ...
(Date:3/27/2017)... Birmingham, Clarkston, and Lake Orion, Michigan (PRWEB) , ... ... ... can affect weight loss results. The comprehensive weight management program at Women’s ... begins with an initial evaluation and physical exam. The specialists at ...
(Date:3/27/2017)... ... March 27, 2017 , ... Kwalu, a leading provider of ... row; they are the recipient of the prestigious “Best Overall Design Strategy in ... at Design Connections 2017. Top A&D professionals from leading firms, furniture manufacturers and ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer Society , ... more than 95%. Once the cancer spreads to other organs, bones, or lymph nodes, ... how to avoid this latter group, tune in to Lifestyle Magazine on ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
(Date:3/27/2017)... March 27, 2017  BERG, a biopharmaceutical ... biological research approach, today announced that the ... discovery of new data using a cold-induced ... fat metabolism. Joslin Diabetes Center led the ... platform for analysis of samples.  The findings ...
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
Breaking Medicine Technology: